-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5174 Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Program: Oral and Poster Abstracts
Session: 908. Outcomes Research: Myeloid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, Adult, APL, Clinical Research, Diseases, Real-world evidence, Adverse Events, Myeloid Malignancies, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Angela M. Canadeo, PharmD1*, Emily Giever, MSN, RN2*, Aniko Szabo, PhD3*, Yuchen Jin3*, Eric S. Winer, MD4, Talha Badar, MD5, Jaclynn Campos, PA-C6*, Chenyu Lin, MD7, Clare E Anderson, MD8*, Rory M. Shallis, MD9, Tinatin Muradashvili, MD10*, Alexander Coltoff, MD11, Qi Jin Guo, MD12*, Anand Ashwin Patel, MD13, Leah A Goldberg, MD14*, Yasmin Abaza, MD15, Maaridge Fariduddin, MABS15*, Rauna Ayoub, MABS15*, Charles Foucar, MD16, Nhi Nai, DO17*, Vamsi K. Kota, MD18, Mark Dalgetty, DO19*, Matthew Gold, DO20*, Medha Guduru21* and Ehab L. Atallah, MD22

1Froedtert & Medical College of Wisconsin, Milwaukee, WI
2Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3Medical College of Wisconsin, Milwaukee, WI
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
5Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL
6Mayo Clinic Cancer Center, Jacksonville, FL
7Duke Cancer Institute, Duke University School of Medicine, Durham, NC
8Department of Medicine, Duke University School of Medicine, Durham, NC
9Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, Killingworth, CT
10Department of Hematology, Yale University, Cliffside Park, NJ
11Medical University of South Carolina, Charleston, SC
12Medical University of South Carolina (MUSC), Charleston, SC
13Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
14Department of Internal Medicine, University of Chicago Medical Center, Chicago, IL
15Northwestern University, Chicago, IL
16University of New Mexico School of Medicine, Albuquerque, NM
17University of New Mexico, Albuquerque, NM
18Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
19Georgia Cancer Center, Augusta, GA
20Medical College of Georgia, Augusta, GA
21Medical College of Georiga, Augusta, GA
22Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

Background:

Acute promyelocytic leukemia (APL) is one of the most treatable leukemias in the current era, with cure rates upwards of 90%. Early mortality due to coagulopathies often seen at diagnosis is a major driver of adverse outcomes. Prompt initiation of all-trans retinoic acid (ATRA) is crucial for suspected APL, as it is known to reverse these coagulopathies. Chemotherapy-free protocols consisting of arsenic trioxide (ATO) and ATRA have become the standard of care for low-risk APL with high cure rates and reduced hematologic toxicities. For high-risk disease, there are multiple treatment options that have not been compared. Since APL is rare, there is a lack of real-world data for this disease. This retrospective review aimed to assess the outcomes of APL patients (pts) across multiple institutions and to examine the most common induction regimens, characteristics linked to early (30-day) mortality, and supportive care strategies.

Methods:

This retrospective study involved 9 institutions in the US and was conducted through the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Data included pts admitted from 8/5/2006 through 2/3/2024 with a confirmed diagnosis of APL. Each institution received a data-collection form and contributed data on APL pts from presentation to last follow-up. Key data categories included patient demographics, presenting laboratory and molecular data, treatment regimen, supportive care, and patient outcomes.

Results:

Data for 412 pts were identified with a median age of 51 (range 17-90) and 49% were female. Cardiovascular comorbidities were present in 44% of pts and 16% had a known pulmonary comorbidity. At presentation 109 (27%) had high risk-disease, defined as a white blood cell count (WBC) greater than 10 x 109/L. A FLT3 mutation was seen in 50% of tested pts, WT1 (22%), KRAS (3.6%), and NRAS (6.5%). The median WBC at presentation was 2 x 109/L (range: 0-166 x 109/L) and the median platelet count was 27 x 109/L (range: 2.0-315 109/L). Twenty-six percent presented with grade 2+ thrombosis, bleeding, or both. A higher percentage of pts with high-risk vs. low-risk disease presented with grade 2+ thrombosis, bleeding, or both (43% vs. 20%), DIC (60% vs. 36%), and mutated FLT3 (81% vs. 37%).

The majority of pts received a chemotherapy-free induction regimen consisting of ATRA plus ATO. It was determined that 36 (8.7%) pts received induction with intermittent ATO plus ATRA (Burnett AK, Lancet Oncol 2015), 276 (67%) received daily ATO plus ATRA (Ravandi F, J Clin Oncol 2009 and Lo Coco, NEJM 2013), and 70 (17%) received a regimen inclusive of an anthracycline plus ATRA. Eleven pts did not start an induction regimen other than single-agent ATRA due to early death, while 19 had their regimen classified as “other” because they did not follow a conventional induction path. In total, 295/358 (82%) received ATRA within 24 hours of admission. At least 1 dose of gemtuzumab ozogamicin was given to 58 (14%) pts, of which 35 (60%) were considered high risk. The incidence of differentiation syndrome (DS) was 37% (n=154). Among the 243 pts who received steroid prophylaxis, 30% developed DS, compared to 52% of those who did not receive prophylaxis.

Among the 360 pts with at least 1 available PCR result after starting induction, 94% achieved PCR-negativity. The 30-day mortality rate was 6.6%. On univariate analysis, presenting variables associated with a higher 30-day mortality include older age, diabetes, cardiovascular comorbidities, thrombosis or bleeding, DIC, eGFR < 60, elevated total bilirubin and D-dimer levels, and high-risk disease. The median overall survival (OS) of the cohort was not reached, and the 5- and 10-year OS was 88% (95% CI: 84-91%) and 79% (95% CI: 72-87%) respectively. The cumulative incidence of relapse at 3 years was 2.7% (95% CI: 1.4 – 5.1%), with no additional relapses observed. The incidence of CNS relapse at 3 years was 0.9% (95% CI: 0.3% - 2.8%), with 2 of the 4 pts classified as high-risk.

Conclusion:

This is the largest real-world evidence data collection in the US evaluating the outcome of pts with APL in the current era, inclusive of ATO as front-line induction. Outcomes for this disease remain extremely positive, with low 30-day mortality rates noted in this study along with durable OS rates and low incidence of relapse. Additional information on outcomes, safety, and supportive care will be presented at the meeting.

Disclosures: Badar: pfizer: Other: Advisory board; Morphosys: Other: Advisory Board; Takeda: Other: advisory board . Lin: Autolus: Consultancy; Rigel: Consultancy; ADC Therapeutics: Consultancy. Shallis: Servier: Consultancy, Honoraria, Other: Steering Commitee; Rigel: Consultancy, Honoraria; Kura Oncology: Consultancy, Honoraria; Gilead Sciences, Inc: Consultancy, Honoraria. Patel: Pfizer: Research Funding; Sobi: Honoraria; AbbVie: Honoraria; Sumitomo: Research Funding; Bristol Myers Squibb: Honoraria; Kronos Bio: Research Funding. Abaza: AbbVie: Research Funding; Biomea Fusion: Research Funding; Novartis: Research Funding; Curis: Research Funding; Biosight: Research Funding; ALX Oncology: Research Funding; Geron: Consultancy; BMS/Celgene: Consultancy; Rigel: Consultancy; Astellas: Consultancy; Servier: Consultancy; Pfizer: Consultancy; Kite/Gilead: Consultancy; Daiichi-Sankyo: Consultancy; Servier: Consultancy. Foucar: Novartis: Research Funding. Kota: Novartis: Honoraria; Pfizer: Honoraria; Kite Pharma: Honoraria. Atallah: Novartis Pharmaceuticals Corporation: Honoraria.

*signifies non-member of ASH